Fosun gets Chinese rights to Ardelyx's tenapanor
Gastrointestinal company Ardelyx Inc. (NASDAQ:ARDX) granted Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) exclusive rights in China to develop and commercialize tenapanor (AZD1722, RDX5791) to treat irritable bowel syndrome with constipation (IBS-C) and to treat hyperphosphatemia related to chronic kidney disease.
Ardelyx will receive $12 million up front and is eligible for $113 million in milestones, plus tiered royalties in the mid-teens to 20 percent...
BCIQ Target Profiles
Solute carrier family 9 sodium hydrogen exchanger member 3 (SLC9A3) (NHE3)